Roche showcases emerging new medicines

Swiss pharma giant Roche (ROG: SIX) has provided an update on its late-stage pipeline at an investor event in London, including promising investigational medicines for multiple sclerosis, asthma, hemophilia, eye disease and cancer.

In these and other areas, Roche expects as many as seven major read-outs from clinical trials with new molecular entities or line extensions for existing medicines up to the end of 2017, adding to the seven read-outs already achieved in 2015. These are expected to offset competition from biosimilar versions of its older drugs once their patents start to expire in 2017.

Addressing unmet need in melanoma, lung cancer and multiple sclerosis